2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 187

Detection of Power Doppler Ultrasound Signals in Rheumatic Diseases Using Superb Microvascular Imaging (SMI): Comparison with Conventional Power Doppler Ultrasound
Abstract Number: 1525

Detection of Previous Tuberculosis Infections in Japanese Rheumatoid Arthritis Patients: Comparison of Two Interferon-G Releasing Assays and the Impact of CD4-Positive Lymphocytes
Abstract Number: 2924

Determinants of Damage in an SLE Cohort: Real World Data
Abstract Number: 2672

Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States
Abstract Number: 363

Determination of the Osteoporotic Vertebral Fractures By a New Quantitative Approach: Intervertebral Volume Index
Abstract Number: 2501

Determining the Rate of Cardiovascular Risk Assessment in Patients with Rheumatoid Arthritis at Federally Qualified Outpatient Continuity Clinic – a Performance Improvement Project
Abstract Number: 1190

Developing an Introductory Musculoskeletal Ultrasound Curriculum for Rheumatology Fellows
Abstract Number: 1917

Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 419

Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis
Abstract Number: 2445

Development and Usability Testing of an Ipad-Based Psycho-Educational Game for Children with Juvenile Idiopathic Arthritis and Their Parents
Abstract Number: 2679

Development and Validation of a HAQ-Derived Tool to Detect Muscle Mass Deficits in Rheumatoid Arthritis
Abstract Number: 2632

Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases
Abstract Number: 3093

Development and Validation of Diagnostic Criteria for Cryopyrin Associated Periodic Syndromes
Abstract Number: 1484

Development and Validation of Juvenile Autoinflammatory Disease Multidimensional Assessment Report (JAIMAR)
Abstract Number: 828

Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].